Form 4: Igor Bilinsky, Iovance Biotherapeutics COO, Reports Acquisition of Restricted Stock Units

Igor Bilinsky, Chief Operating Officer of Iovance Biotherapeutics, reported the acquisition of restricted stock units (RSUs) on March 1, 2024.

Summary

• On March 1, 2024, Igor Bilinsky, the Chief Operating Officer of Iovance Biotherapeutics, acquired 105,470 restricted stock units (RSUs) that vest over three years.
• An additional 46,875 RSUs were acquired, vesting over six months and one year.
• The RSUs represent a contingent right to receive shares of Iovance Biotherapeutics common stock.
• The price of the derivative security is $0.00.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard transaction of RSUs being granted to an executive. It doesn't inherently indicate positive or negative sentiment, but rather a routine part of executive compensation.

Positives

• The acquisition of RSUs by a key executive may indicate confidence in the company's future performance.

Future Outlook

The vesting schedules for the RSUs are tied to continued employment with Iovance Biotherapeutics.

Industry Context

This filing is a routine disclosure related to executive compensation and is common in the biotechnology industry.

Stakeholder Impact

• The granting of RSUs aligns the executive's interests with those of the shareholders, potentially incentivizing performance that benefits the company's stock price.

Key Dates